WFH Guidelines by Topic Area
WFH Guideline Topics are carefully selected to address all aspects of Hemophilia Management and Care.
Table of Contents
Guidelines
These recommendations cover genetic testing of people with suspected or diagnosed hemophilia and their ‘at-risk’ female family members, to define the specific genetic mutation, predict risk of inhibitor development, identify asymptomatic carriers, and more.
These recommendations provide guidance for serious bleeding episodes—such as intracranial, renal, gastrointestinal/abdominal, or joint hemorrhages—where prompt recognition of symptoms and immediate treatment is critical.
This guideline provides additional context and information for the treatment of patients who have developed inhibitors, or antibodies against Clotting Factor.
Here you will find recommendations around specific management issues in hemophilia that require a tailored approach, such as care for carriers, newborns, surgical patients, and older adults with comorbidities.
These recommendations focus on musculoskeletal complications in hemophilia that result from recurrent joint and muscle bleeds, which can progress from acute hemarthrosis to chronic synovitis and permanent joint damage.
This topic covers outcome assessment in hemophilia and evaluates multiple dimensions of disease impact, including body structure and function, activities of daily living, participation, health status, and overall disease burden.
This new topic addresses all aspects of AAV Gene Therapy care and includes recommendations for the hemophilia treatment center, healthcare team, and people with hemophilia. Shared decision-making is essential when deciding to begin the AAV gene therapy process.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nunc vulputate libero et velit interdum, ac aliquet odio mattis. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.
